



ISSN: 2277- 7695

TPI 2015; 4(3): 68-73

© 2015 TPI

www.thepharmajournal.com

Received: 26-03-2015

Accepted: 25-04-2015

Iftikhar Ahsan

Department of Health Science,
Faculty of Pharmacy, Research
Centre, Shri Venkateshwara
University, NH-24,
Venkateshwara Nagar,
Rajabpur, Gajraula, Amroha,
(U.P.), Pin Code 244236, India.

K.K. Sharma

Department of Health Science,
Faculty of Pharmacy, Research
Centre, Shri Venkateshwara
University, NH-24,
Venkateshwara Nagar,
Rajabpur, Gajraula, Amroha,
(U.P.), Pin Code 244236, India.

Correspondence:

Iftikhar Ahsan

Department of Health Science,
Faculty of Pharmacy, Research
Centre, Shri Venkateshwara
University, NH-24,
Venkateshwara Nagar,
Rajabpur, Gajraula, Amroha,
(U.P.), Pin Code 244236, India.

Pharmacological evaluation of newly synthesized imidazole derivatives containing 2-(2-hydroxyphenyl)-4, 5-diphenyl imidazole moiety

Iftikhar Ahsan and K.K. Sharma

Abstract

A series of imidazole derivatives (4 **a-e**) have been synthesized from 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole-1-yl)-acetic acid hydrazide under various reaction conditions. Elemental analysis, IR, ¹H NMR and mass spectral data confirmed the structure of the newly synthesized compounds. All the synthesized imidazole derivatives have been investigated for their anti-inflammatory, anti-bacterial and antifungal effect and showed moderate to good activity

Keywords: 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole, anti-inflammatory, antimicrobial, antifungal

Introduction

Resistance to number of antimicrobial agents among a variety of clinically significant species of bacteria are becoming increasingly important global problem. There are various problems arising with the use of antimicrobials such as local tissue irritation, interference with wound healing process, hypersensitivity reactions, systemic toxicity, narrow antimicrobial spectrum, emergence of resistance [3]. So the increasing clinical importance of drug-resistant microbial pathogens has lent additional urgency in microbiological and antifungal research. Wide variety of heterocyclic systems have been explored for developing pharmaceutically important molecules.

Imidazole has become an important part of many pharmaceuticals. Synthetic imidazoles are present in many fungicides and antifungal, antiprotozoal, and antihypertensive medications. Imidazole is part of the theophylline molecule, found in tea leaves and coffee beans, which stimulates the central nervous system. The nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in the treatment of rheumatoid arthritis, and other inflammatory diseases. Even with the advent of COX-2 inhibitors, their long term use has been associated with gastrointestinal ulceration, bleeding and nephrotoxicity [5-6]. The tendency of many acidic drugs to accumulate in the stomach walls soon after oral absorption, as evidenced by radio autography, has been considered as a contributory factor for GI irritation [7]. The adverse effect of NSAID's are mediated via inhibition of prostaglandin synthesis from arachidonic acid by non-specific blocking of the enzyme cyclooxygenase leading to vasoconstriction and reversible mild renal impairment [8]. It has been reported in the literature that certain five membered heterocyclic compounds possess interesting anti-inflammatory activity with lesser GI side effect [6, 8]. Among heterocyclic compounds, imidazole ring bearing compounds are reported to have significant anti-inflammatory activity [6, 9]. Multi drug treatment of inflammatory conditions associated with microbial infections poses a unique problem especially for patients with impaired liver or kidney functions. Hence, mono therapy with a drug having both anti-inflammatory and antimicrobial activities is highly desirable, both from the pharmacoeconomic as well as patient compliance points of view [7-15]. Encouraged by these observations and in continuation of the research programme on the synthesis of five membered heterocyclic compounds, herein is reported the synthesis of various derivatives of 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole.

The reaction sequence leading to the formation of the desired heterocyclic compounds are outlined in **Scheme I**. 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole-1-yl)-acetic acid hydrazide **3** was prepared by treating 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole with ethyl chloroacetate in the presence of anhydrous acetone and potassium carbonate followed by reaction with hydrazine hydrate in absolute ethanol. Hydrazide **3** is treated with

phenylisothiocyanates derivatives. Hydrazone **3** on treatment with various substituted phenylisothiocyanates gave N¹-(2-(2-hydroxyphenyl)-4,5-diphenyl-imidazol-1-yl-ethanoyl)-N⁴-substitutedphenyl thiosemicarbazide.

The ¹H NMR spectra of compound **4a** showed a multiplet δ 7.2-7.5 for 18 aromatic protons of phenyl ring of imidazole derivatives. A peak was also obtained at δ 8.12 showing the presence of 1H of NH. A singlet was obtained at another δ 4.52-4.55 for NCH₂ protons. Furthermore, two singlets were also obtained at δ 12.70 and δ 10.88 of CONH and CSNH-group respectively.

The ¹H NMR spectra of compound **4b** showed a multiplet δ 6.91 showing the presence of 15 aromatic protons of phenyl ring attached to imidazole derivatives. A doublet was also observed at δ 8.08-8.11 showing the presence of remaining two protons of phenyl ring attached to imidazole. Singlets were obtained at δ 3.73, δ 4.45 and δ 12.75 for methoxy, N-CH₂ protons and -CONH- group respectively and a singlet was also obtained at 12.41 for one proton of CSNH group. The IR spectrum of compound showed absorption peaks at 1502 cm⁻¹, C=C stretching; 1606 cm⁻¹, C=N; 1456 cm⁻¹, C-N stretching; 3032 cm⁻¹, ArC-H stretching, 1751 cm⁻¹, -CONH- stretching, 1208 cm⁻¹, C=S stretching, and 1166 cm⁻¹ methoxy stretching.

The ¹H NMR spectra of **4c** compound showed a multiplet at δ 7.21-7.53 for 15 aromatic protons of phenyl rings attached to imidazole. A doublet was also observed at δ 8.07-8.09 showing the presence of remaining two protons of phenyl ring attached to imidazole. Two singlets were also obtained at δ 2.28 and δ 4.53 for CH₃ and N-CH₂ protons respectively. Furthermore, another singlet was also obtained at δ 12.59 of -CONH- proton, 12.41 for one proton of CSNH group and one peak at 8.08 for one proton of -NH- group. The IR spectrum of compound showed absorption peaks at δ 1539 (C=C), (aromatic C-H), 3196 (NH), δ 1892 (CONH), 1668 (C=O), 1596 (C=N), 1207 cm⁻¹ (C=S) stretching.

The ¹H NMR spectra of **4d** compound showed a multiplet at δ 7.21-8.02 for 17 aromatic protons of phenyl rings attached to imidazole. A singlet was obtained at δ 4.52 for N-CH₂ protons. Three singlets were also obtained at δ 12.80, δ 8.14 and δ 11.08 of -CONH-, -NH- and -CSNH- group respectively. The IR spectrum of compound showed absorption peaks at δ 4.99 (C-Cl), δ 3032 (aromatic C-H), δ 3196 (NH), δ 1751 (CONH), 1651 (C=O), 1606 (C=N), 1208 cm⁻¹ (C=S) stretching.

The ¹H NMR spectra of **4e** compound showed a multiplet at δ 7.22-7.67 for 17 aromatic protons of phenyl rings attached to imidazole. A singlet was obtained at δ 4.49 for N-CH₂ protons. Three singlet were also obtained at δ 12.83, δ 11.16 and δ 12.69 of -CONH-, -NH- and -CSNH- group respectively. The IR spectrum of compound **4e** showed absorption peaks at δ 4.99 (C-Cl), δ 3032 (aromatic C-H), δ 3196 (NH), δ 1751 (CONH), 1651 (C=O), 1591 (C=N), 1101 cm⁻¹ (C=S), 1547 cm⁻¹, C=C stretching. The structure of **4e** compound was

further characterized by mass spectra: molecular ions peaks at m/z M⁺ 500.2. Further peaks at m/z =383, 319 and 297.

Biological Studies

Adult male Wister strain rats of either sex, weighing 180-200 gm were used. The animals were allowed food and water *ad libitum*. They were housed at room at 25 ± 2°C, and 50 ± 5% of relative humidity with 12 hr light/dark cycle. The animals were randomly allocated into groups at the beginning of all the experiment. All the test compounds and reference drug were administered orally, suspended in 0.5% carboxymethyl cellulose (CMC) solution.

Anti-inflammatory activity

The test was performed by the method of winter *et al.* [16] on the group of six animals in each. Carrageenan solution (0.1% in sterile 0.9% NaCl solution) in a volume of 0.1 ml was injected subcutaneously into the sub plantar region of the right hind paw of each rat, 1 hr after the administration of test compounds and standard drug indomethacin (10 mg/kg, p.o). One group was kept as control, receiving only 0.5% carboxymethyl cellulose solution. The right hind paw volume was measured before and after 4 hr of carrageenan treatment by means of a plethysmometer. The percentage anti-inflammatory activity was calculated according to the following formula.

Percentage anti-inflammatory activity = $(1 - V_t/V_c) \times 100$, where V_t represents the mean in paw volume in rats tested with test compounds and V_c represents the mean increase in paw volume in control group of rats.

Data are expressed as mean ± SEM. The student *t*-test was applied to determine the significance of the difference between the control group and rats treated with the test compounds. The anti-inflammatory activity of the newly synthesized compounds **4a**, **4b**, **4c**, **4d** and **4e** were compared with the standard drug indomethacin. At the same oral dose, indomethacin showed 71.56% inhibition of rat paw edema whereas the tested compounds (**4a-e**) showed inhibition ranging from 41.90 to 83.40% after 4 hr (**Table I**). The compounds **4c** and **4d** having methyl, 4-Fluoro groups showed moderate activity (53.90 and 54.01%) in comparison to standard drug indomethacin (71.56%). The compounds **4e** having 4-chloro group showed better activity (83%) in comparison to standard drug indomethacin (71.56%). It was noted that when the phenyl ring of thiosemicarbazide of triphenylimidazole moiety was substituted by methylphenyl group (**4c**) and fluorophenyl groups (**4d**), there was marked increase in the anti-inflammatory activity (from 40.81% to 54%) respectively. The compounds **4e** having 2-hydroxyphenyl group showed enhanced activity (83.40 %) greater than the standard drug indomethacin (71.56%).

Table I: Anti-inflammatory activity of compounds **4a**, **4b**, **4c**, **4d** and **4e**

Compd.	Mean values (±SEM) of oedema Volume		Anti-inflammatory activity (% inhibition±SEM)	
	3 hr	4 hr	3 hr	4 hr
Control	1.74±0.076	1.62±0.082	----	---
Indomethacin	0.50±0.026	0.46±0.029	71.10±1.42	71.56±1.42
4a	1.06±0.048	0.97±0.047	39.32±1.37*	40.81±1.40*
4b	1.05±0.042	0.94±0.043	40.73±1.87*	41.90±1.21*
4c	0.82±0.031	0.74±0.035	53.00±1.67*	53.90±1.39*
4d	0.83±0.028	0.75±0.028	52.44±1.28*	54.01±1.24*
4e	0.32±0.031	0.25±0.018	81.98±1.77**	83.40±1.06*

Anti-inflammatory activity of the test compounds were compared w.r.t. standard drug. Data were analyzed by student's *t* test for n=6; *p<0.0001, **p<0.01, ***p<0.5

The other two imidazole derivatives 4a and 4b having phenyl and 4-methoxy phenyl group respectively showed poor anti-inflammatory activity (40.81 and 41.90 %). It was observed that chloro group substitution resulted in the significant increase of anti-inflammatory activity (83.40 %). The results of anti-inflammatory activity clearly indicated that among all four imidazole derivatives, the chlorophenyl substituted imidazole derivative were the most active compounds of the series.

Antibacterial and antifungal activities

All the compounds have been screened for both antibacterial and antifungal activities using cup plate agar diffusion method¹⁷ by measuring the inhibition zone in mm. Ofloxacin (100 µg/mL) was used as standard drug for antibacterial activity, and Voriconazole (100 µg/mL) as a standard drug for antifungal activity. The compounds were screened for

antibacterial activity against *E. coli*, *B. subtilis* and *S. aureus* in nutrient agar medium, and for antifungal activity against *Candida albicans* in Sabouraud's dextrose agar medium. These sterilized agar media were poured into Petri-dishes and allowed to solidify. On the surface of the media microbial suspensions were spread with the help of sterilized triangular loop. A stainless steel cylinder of 8 mm diameter (pre-sterilized) was used to bore cavities. All the synthesized compounds (100 µg/ml) were placed serially in the cavities with the help of micropipette and allowed to diffuse for 1 hr. DMF was used as solvent for all compounds and as control. These plates were incubated at 37°C for 34hr and 28°C for 48hr, for antibacterial and antifungal activity respectively. The zone of inhibition observed around cup after respective incubation was assured and percent inhibition of the compounds was calculated. Results were presented in Table II.

Table II- Antibacterial and antifungal activity of compounds 4a, 4b, 4c, 4d and 4e

Compd.	Antibacterial activity						Antifungal activity	
	<i>E. coli</i>		<i>B. subtilis</i>		<i>S. aureus</i>		<i>C. albicans</i>	
	Zone of inhibition (mm)	% inhibition	Zone of inhibition (mm)	% inhibition	Zone of inhibition (mm)	% inhibition	Zone of inhibition (mm)	% inhibition
4a	22	61.11	14	43	14	48	20	75
4b	22	61.11	15	47	21	72	20	69
4c	23	67	15	47	20	69	17	58.6
Xd	22.5	62.5	20	62	19	65.5	20	69
Xe	19	52	12	50	22	75	20	68.5
Ofloxacin	36	100	32	100	29	100	---	---
Voriconazole	---	---	---	---	---	---	29	100

The 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole derivative 4e, 4b and 4c having 2-chlorophenyl group, 4-methoxyphenyl group and 4-methylphenyl group showed highest activity (75%, 72% and 69% respectively) against *S. aureus*. The compound 4c and 4d having 4-methylphenyl group and 4-fluorophenyl group showed highest activity (67% and 62.5% respectively) against *E. coli* when compared with standard drug Ofloxacin. Rest of the compound showed moderate to good activity against *E. coli*, *B. subtilis* and *S. aureus*. The derivative 4e having chloro phenyl group showed highest activity against (75%).

All the derivatives (4a-e) showed good antifungal activity (68 to 75%) against *Candida Albicans*. The derivative 4a and 4b having phenyl and 4-methoxy phenyl ring showed highest antifungal activity (75%) against *C. albicans*. The compound 4d also showed good activity. When 4-methoxy phenyl group replaced by 4-methylphenyl in compound 4c and 4-chlorophenyl in compound 4e respectively, there was slight decrease of antifungal activity (58.6% and 68.5 %). The imidazole derivative having 4-methylphenyl group showed minimum activity. Thus, it is concluded from the screening results that imidazole derivative 4a and 4b were most effective against at a concentration of 100 µg/ml. Overall screening result show variable trend of effect of imidazole derivative (4a-e) against all the micro-organism.

Experimental Section

All the chemicals used in the synthesis were supplied by E. Merck and S. D. Fine Chemicals. Melting point was determined by open capillary tube method and is uncorrected. Homogeneity of the compounds were checked on thin layer chromatography using iodine vapors as visualizing agent. IR spectra were obtained on a Perkin-Elmer 1720 FT-IR

spectrometer (KBr pellets). ¹H NMR spectra were obtained on a Bruker DRX-300 (300 MHz FT NMR) spectrometer in CDCl₃ using tetramethylsilane (TMS) as the internal reference (chemical shifts in δ, ppm). Mass spectra were recorded on a Jeol SX-102 spectrometer. Synthesis of 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole **1** was carried out by using chlorobenzaldehyde by the methods reported in literature¹⁸.

Synthesis of 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole (1): Eqimolar quantity of benzyl (2.65 gm), ammonium acetate (5 gm) and salicylaldehyde (1.5 ml) were dissolved in 50 ml glacial acetic acid in a 100 ml RBF containing a magnetic stirrer. The reaction mixture was heated to reflux for 5 hrs on an oil bath with stirring. The 300 ml cooled water was added to reaction mixture which resulted in precipitation of product. The product immediately filtered and neutralized with 5% ammonium solution. The compound was recrystallized from absolute ethanol to yield colourless crystalline compound **2**. Yield 65%; m.p. 260°C; ¹H NMR (CDCl₃) of compound shows a double doublet at δ 7.92-7.94 ; δ 8.21-8.50 and δ 8.50-8.53 respectively showing presence of 4H-protons of 2-phenyl ring attached to imidazole. A multiplet was obtained at δ 7.32-7.78 showing the presence of remaining 10H protons of 4, 5-diphenyl rings. A singlet was also obtained at 13.09 showing the presence of NH protons.

Synthesis of 2-(2-hydroxyphenyl)-4, 5-diphenyl-imidazole-1-yl)-acetic acid ethyl ester 2: A mixture of 2-(2-hydroxyphenyl)-4, 5-diphenyl-1*H*-imidazole (0.03 mole) and ethyl chloroacetate (0.01 mole) in dry acetone (40 mL) was refluxed on a heating mantle for 30 hr. The reaction mixture was cooled to RT. The crystals thus obtained was filtered, washed with water, dried and purified by recrystallization from

ethanol to yield colourless crystalline compound **2**. Yield 66%; m.p. 260°C; IR (KBr, cm^{-1}): 8.33.86,7.64.48,6.72.64 (C-Cl); 3026.85 (aromatic C-H);1668 (C=O), 1595 cm^{-1} (C=N); $^1\text{H NMR}$ (CDCl_3): δ 1.31-1.37 (t, 3H, CH_3), 4.08-4.16 (q, 2H, CH_2), 4.48 (s, 2H, NCH_2), 7.20-7.45 (m, 10H, ArH), δ 8.04 - δ 8.10 (4H, 3d, ArH); MS: m/z 382 (M^+).

Synthesis of 2-(2-(2-hydroxyphenyl)-4,5-diphenyl-imidazole-1-yl)-acetic acid hydrazide 3: A mixture of 2-(2-hydroxyphenyl)-4, 5-diphenyl-imidazole-1-yl)-acetic acid ethyl ester (0.01 mole) and hydrazine hydrate (0.05 mole) in ethanol (50 ml) was refluxed on water bath for 12 hr. The reaction-mixture was cooled to RT. The crystals thus obtained were filtered, washed with water, dried and purified by recrystallization from ethanol to yield colourless crystalline compound **3**. Yield 68%; m.p. 240°C; IR (KBr): 8.33.86,7.64.48,6.72.64 (C-Cl); 3026.85 (aromatic C-H); 1595 cm^{-1} (C=N); 3038 (NH), 1694 (C=O); $^1\text{H NMR}$ (CDCl_3): δ 5.35 (s, 2H, NCH_2), 5.1 (d, 2H, NH_2), 7.20-7.5 (m, 10H, ArH), δ 8.04 - δ 8.10 (4H, 2d, ArH); 9.8 (bs, 1H, s, CONH); MS: m/z 368 (M^+).

General method of synthesis of N^1 -(2-(2-hydroxyphenyl)-4,5-diphenyl-imidazol-1-yl-ethanoyl)- N^4 -substituted phenyl thiosemicarbazide: A mixture of acid hydrazide (0.01 mole) and substituted phenyl isothiocyanate (0.01 mole) in absolute ethanol (50 ml) was refluxed on a water bath for 6 hr. The reaction-mixture was concentrated and allowed to stand at RT overnight. The needle shaped crystals of thiosemicarbazide thus obtained were filtered, washed with petroleum ether and purified by re-crystallization from ethanol.


N^1 -(2-(2-hydroxyphenyl)-4,5-diphenyl-imidazol-1-yl-ethanoyl)- N^4 -phenyl thiosemicarbazide, 4a: Yield 52%; m.p. 228°C; IR (KBr): δ 1502 (C=C), δ 3032 (aromatic C-H), 3196 (NH), δ 1751 (CONH), 1683 (C=O), 1597 (C=N), 1099 cm^{-1} (C=S). $^1\text{H NMR}$ (CDCl_3): 4.53 (s, 2H, NCH_2), 7.2-7.5 (m, 19H, ArH), 8.12 (bs, 1H, NH) 10.88 (bs, 1H, CSNH), 12.70 (bs, 1H, CONH); MS: m/z 533 (M^+).

N^1 -(2-(2-hydroxyphenyl)-4,5-diphenyl-imidazol-1-yl-ethanoyl)- N^4 -4-methoxyphenyl thiosemicarbazide, 4b: Yield 49.3%; m.p. 230°C; IR (KBr): δ 1502 (C=C), δ 3032 (aromatic C-H), 3196 (NH), δ 1751 (CONH), 1668 (C=O), 1606 (C=N), 1208 cm^{-1} (C=S) and 2988 alkyl -CH- stretching; $^1\text{H NMR}$ (CDCl_3): δ 3.73 (s, 3H, OCH_3), 4.45 (s, 2H, NCH_2), δ 6.91 (m, 15H, ArH), δ 8.08-8.11(d, 2H, ArH), δ 10.91 (bs, 1H, NH), δ 12.41 (bs, 1H, CSNH), δ 12.75 (bs, 1H, CONH); (M^+). m/z 530 (M^+).

N^1 -(2-(2-hydroxyphenyl)-4,5-diphenyl-imidazol-1-yl-ethanoyl)- N^4 -4-methylphenyl thiosemicarbazide, 4c: Yield 52%; m.p. 238°C; IR (KBr): δ 1539 (C=C), δ 1044 (C-F), δ 3037 (aromatic C-H), 3196 (NH), δ 1892 (CONH), 1668 (C=O), 1596 (C=N), 1207 cm^{-1} (C=S) and 2988 alkyl -CH- stretching; $^1\text{H NMR}$ (CDCl_3): δ 2.28 (s, 3H, CH_3), 4.53 (s, 2H, NCH_2), δ 7.21-7.53 (m, 15H, ArH), δ 8.07-8.09 (d, 2H, ArH), δ 8.08 (bs, 1H, NH), δ 12.41 (bs, 1H, CSNH), δ 12.59 (bs, 1H, CONH); MS: m/z 517 (M^+).

N^1 -(2-(2-hydroxyphenyl)-4,5-diphenyl-imidazol-1-yl-ethanoyl)- N^4 -4-fluorophenyl thiosemicarbazide, 4d: Yield 48.8%; m.p. 251°C; IR (KBr): δ 4.99 (C-Cl), δ 1044 (C-F), δ 3032 (aromatic C-H), δ 3196 (NH), δ 1751 (CONH), 1651 (C=O), 1606 (C=N), 1208 cm^{-1} (C=S); $^1\text{H NMR}$ (CDCl_3): δ 4.52 (s, 2H, NCH_2), δ 7.21-8.02 (m, 17H, ArH), 8.14 (bs, 1H, NH), 11.08 (bs, 1H, CSNH), 12.80 (s, 1H, CONH); MS: m/z 521 (M^+).

N^1 -(2-(2-hydroxyphenyl)-4,5-diphenyl-imidazol-1-yl-ethanoyl)- N^4 -4-chlorophenyl thiosemicarbazide, 4e: Yield 48%; m.p. 223°C; IR (KBr): δ 4.99 (C-Cl), δ 3032 (aromatic C-H), δ 3196 (NH), δ 1751 (CONH), 1651 (C=O), 1591 (C=N), 1101 cm^{-1} (C=S); $^1\text{H NMR}$ (CDCl_3): δ 4.49 (s, 2H, NCH_2), 7.22-7.67 (m, 17H, ArH), 11.16 (bs, 1H, NH), 12.69 (bs, 1H, CSNH), 12.83 (bs, 1H, CONH); MS: m/z 538 (M^+), 540 ($\text{M}^+ + 2$).




Scheme I

Graphical Abstract

Pharmacological evaluation of newly synthesized imidazole derivatives containing 2-(2-hydroxyphenyl)-4, 5-diphenyl imidazole moiety

A series of imidazole derivatives (**4a**, **4b**, **4c**, **4d** and **4e**) have been synthesized from (2-(2-hydroxyphenyl)-4,5-diphenyl-1-yl)-acetic acid hydrazide under various reaction conditions. Elemental analysis, IR, ¹H NMR and mass spectral data confirmed the structure of the newly synthesized compounds. All the synthesized imidazole derivatives have been investigated for their anti-inflammatory, antibacterial and antifungal activity and showed moderate to good activity.



Acknowledgment

The authors are thankful to Head of the Department of Health, Faculty of Pharmacy for providing laboratory facilities and University Grants Commission (UGC) for providing financial support. Authors are also thankful to Dr. Narendar Kumar Sharma, Director Research of Shri Venkateshwara University for providing required research facility for synthetic and pharmacological studies.

References

1. Kimmey MB. NSAID, ulcers and prostaglandins, *J Rheumatol* 1992; 19:68-73.
2. Tuncbilek M, Kiper T, Altanlar N. *Eur. J. Med. Chem* 2009; 44:1024-1033.
3. A. Burger. *Burger's Medicinal Chemistry and drug Discovery*, 6th edition, John Wiley and Sons, New Jersey, 2003; 5:539-543.
4. Farshori NN, Banday MR, Ahmad A, Khan AU, Rauf A. *Bioorg. Med. Chem. Lett* 2010; 20:1933-1938.
5. Shen TY. Toward more selective antiarthritic therapy, *J Med Chem*, 1981; 24(1):1-5.
6. Ejaz P, Bhojani K, Joshi VR, NSAIDs and kidney, *J Assoc Physicians India*, Aug 2004; 51:632-640.
7. Boschelli DH, Conner DT, Bornemeir DA, Dyer RD, Kennedy JA, Kuipers PJ *et al.* 1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities, *J Med Chem* 1993; 36:1802-10.
8. Tozkoparan B, Gokhan N, Aktay G, Yesilada E, Eartan M. 6-Benzylidenethiazolo[3,2-b]-1,2,4-triazole-5(6H)-ones substituted with ibuprofen: synthesis, characterization and evaluation of anti-inflammatory activity, *Eur J Med Chem* 2000; 35:743.
9. Suzuki F, Kuroda T, Tamura T. *J Med Chem*, 1992; 35:2863.

10. El-Feky SA, Abd el-Samii ZK, *Pharmazie* 1995; 50:341.
11. Amir M, Khan MSY, Zaman MS, *Indian J Chem* 2004; 43B:2189.
12. Plaska E, Shahin G, Kelicen P, Duslu TN, Altinok G. *Il Farmaco* 2002; 57:101.
13. Murthy SN, Srinivasa V. *Indian J Pharmacol* 2003; 35:61.
14. Parekh H, Khunt R, Ladoon K. *Orient J Chem*, 2002; 18:135.
15. Patil LR, Mandhare RPN, Bondge SP, Munde SB, Mane RA. *Indian J Heterocycl Chem* 2003; 12:245.
16. Dundar OB, Ozgen O, Menteşe A, Altanlar N, Atlı O, Kendi E *et al.* *Bioorg Med Chem* 2007; 15:6012.
17. Farghaly AM, Bekhit AA, Park JY. *Arch Pharm Med Chem* 2003; 333:53.
18. Bekhit AA, Azeim TA. *Bioorg Med Chem*, 2004; 12:1935.
19. Bekhit AA, Ashour HMA, Guemei A, *Arch Pharm Chem Life Sci* 2005; 338:167.
20. Barry AL. *The Antimicrobial Susceptibility test: Principle and Practice* (Lea & Febiger Philadelphia), 1976; 180.
21. Winter CA, Risley EA, Nuss GW. *Proc Soc Exp Biol Med* 1962; 111:544.
22. Harwood LM, Moody Cj, Percy JM. *Experimental Organic Chemistry*, 2nd Edⁿ, (Blackwell Scientific Publications, London), 1994, 644.
23. Harwood LM, Moody Cj, Percy JM. *Experimental Organic Chemistry*, 2nd Edⁿ, (Blackwell Scientific Publications, London), 1994, 644.
24. Qasim Sultan Sayyed, *International Journal of Applied Biology and Pharmaceutical Technology*, April-June, 2(2), 2011.
25. Shailesh P Zala, Badmanaban R., Synthesis and biological evaluation of 2,4,5-triphenyl-1H-imidazole-1-yl derivatives, *Journal of Applied Pharmaceutical Science* 2017; 02(07):202-208.
26. Rajiv Dua A, Sonwane SK, Srivastava SKK, Conventional and Greener approach for the synthesis of some novel substituted -4-oxothiazolidine and their 5-arylidine derivative of 5-methyl-benzimidazole: Antimicrobial activities, *Journal of chemical and Pharmaceutical research* 2010, 2(1):415-423.
27. Arshia Parveen, Md. Rafi Sk Ahmed, Kabee A Shaikh, Sudhir PP Deshmukh, Rajendra P Pawar. Efficient synthesis of 2,4,5-triaryl substituted imidazoles under solvent free conditions at room temperature, *Arkivoc* 2007; (xvi):12-18.
28. Bhatnagar A, Sharma PK, Kumar N. A review on Imidazoles: their chemistry and pharmacological potentials, *International Journal of Pharma Tech Research*, Jan-March 2011; 3(1):268-282.
29. Yasodha, A. sivakumar, H. Arunachalam, Synthesis and Biological evaluation of some 2,4,5-triphenyl imidazole derivatives, *Journal of pharmaceutical science and research* 2009; 1(4):127-130.
30. Abdul Jabbar KAI Abodi, Ngam Majed, Sahar AK, Redha IH. Synthesis and characterization of new 1,3-oxazol-(4H)-one derivatives, *American Journal of Organic Chemistry* 2012; 2(6):143-150.
31. Ratheesh, M, Helen A, Anti-inflammatory activity of Ruta graveolens Linn on carrageenan induced paw edema in wistar male rats, *African Journal of Biotechnology* 2007; 6(10):1209-1211,
32. Nazar Trotsko, Maria Doboosz, Ewa Jagiello-Wojtowicz, Cyclization of thiosemicarbazide derivatives of 5-

- arylidine-2,4-dioxothiazolidine-3-acetic acids to 1,3,4-thiazoles and their pharmacological properties, *Acta Poloniae Pharmaceutica-Drug Research* 2007; 64(3):227-231.
33. Ahmad SH Hamad. Compound related to thiosemicarbazide oxadiazoles and thiadiazoles synthesis and spectroscopic studies, Department of Chemistry, University of Tikrit, Iraq.
 34. Sharma S. Sharma PK. Kumar N. Dudhe R. *Der Pharma Chemica* 2010; 2(4):253-263.
 35. Barbucenu SF, Bancescu G, Cretu OD, Draghici C, Bancescu A, Radu-Popescu M. *Rev. Chem. (Bucuresti)*.61.Nr.2., 2010, 140-145.
 36. Kumar GVS. Rajendraprasad Y, Mallikarjuna BP, Chandrashekar SM, Kistayya C. *Eur. J. Med. Chem* 2010; 45:2063-2074.